Related Experiment Video
Updated: Sep 27, 2026
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
[Experimental study on effect of xinkang oral liquid on coxsackie B3 viral myocarditis in mice]
1Department of Pathology, Cardiovascular Institute, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037.
Objective:
To study the therapeutic effect of Xinkang Oral Liquid (XKOL) in treating acute Coxsackie B3 viral myocarditis in mice.
Methods:
Viral myocarditis model was established by intraperitoneal inoculation with Coxsackie B3 virus. Mice were randomly divided into 4 groups randomly, the model group, the positive control group (treated with Ribavilin), the XKOL group and the normal control group. Body weight of mice was weighed at the 5th, 10th and 20th day. Weight, macro- and histopathologic changes of heart were observed by microscope and measured by morphometric quantification, and the data were treated statistically.
Results:
In the XKOL group, the body weight of mice increased, the degree of myocardial necrosis mild and small in size, which has been repaired more completely, the antiviral effect was found in XKOL group.
Conclusion:
XKOL has definite therapeutic effect on viral myocarditis, its effect is better than Ribavilin in protecting myocardium and anti-virus.
Insights
Xinkang Oral Liquid (XKOL) demonstrates significant therapeutic effects against Coxsackie B3 viral myocarditis in mice. This traditional Chinese medicine outperformed Ribavirin in myocardial protection and antiviral activity.
Area of Science:
- Cardiology
- Virology
- Pharmacology
Context:
- Viral myocarditis, particularly Coxsackie B3 virus infections, poses a significant threat to cardiovascular health.
- Current treatments have limitations, necessitating the exploration of novel therapeutic agents.
- Traditional Chinese Medicine (TCM) offers a potential source for effective treatments.
Purpose:
- To evaluate the therapeutic efficacy of Xinkang Oral Liquid (XKOL) in a murine model of acute Coxsackie B3 viral myocarditis.
- To compare the efficacy of XKOL with Ribavirin, a known antiviral drug, in treating viral myocarditis.
- To assess the impact of XKOL on key indicators of myocarditis, including body weight, cardiac pathology, and viral load.
Summary:
- A mouse model of Coxsackie B3 viral myocarditis was established and treated with XKOL, Ribavirin, or vehicle.
- Mice treated with XKOL exhibited improved body weight, reduced myocardial necrosis, and enhanced tissue repair compared to the control group.
- XKOL demonstrated significant antiviral activity and superior myocardial protective effects compared to Ribavirin.
Impact:
- XKOL presents a promising therapeutic option for managing viral myocarditis.
- The findings support the integration of TCM into conventional treatment strategies for cardiovascular diseases.
- Further research into the mechanisms of action of XKOL could lead to the development of new antiviral therapies.